1.Yarchoan R, Uldrick TS: HIV-Associated Cancers and Related Diseases. The New England journal of medicine 2018, 378(22):2145.
2.Meister A, Hentrich M, Wyen C, Hubel K: Malignant lymphoma in the HIV-positive patient. European journal of haematology 2018, 101(1):119–126.
3.Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG et al: Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. Journal of the National Cancer Institute 2013, 105(16):1221–1229.
4.Howlader N, Shiels MS, Mariotto AB, Engels EA: Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016, 25(9):1289–1296.
5.Baptista MJ, Garcia O, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, Abella E, Moreno M, Sancho JM, Feliu E et al: HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. Aids 2015, 29(7):811–818.
6.Li S, Young KH, Medeiros LJ: Diffuse large B-cell lymphoma. Pathology 2018, 50(1):74–87.
7.Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Wolf T et al: Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. British journal of haematology 2015, 168(6):806–810.
8.Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, Young KH: Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Frontiers in Oncology 2019, 9.
9.Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J et al: Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. Aids 2017, 31(18):2493–2501.
10.Wu L, Ehlin-Henriksson B, Zhou X, Zhu H, Ernberg I, Kis LL, Klein G: Epstein-Barr virus (EBV) provides survival factors to EBV(+) diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV(+) DLBCL. Immunology 2017, 152(4):562–573.
11.Deng L, Song Y, Young KH, Hu S, Ding N, Song W, Li X, Shi Y, Huang H, Liu W et al: Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget 2015, 6(28):25061–25073.
12.Tsutsumi Y, Nakayama C, Kamada K, Kikuchi R, Kudo D, Ito S, Matsuoka S, Shiratori S, Yamamoto Y, Naruse H et al: Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Annals of hematology 2017, 96(12):2057–2061.
13.Muncunill J, Baptista MJ, Hernandez-Rodriguez A, Dalmau J, Garcia O, Tapia G, Moreno M, Sancho JM, Martinez-Picado J, Feliu E et al: Plasma EBV-load as an early biomarker and prognostic factor of HIV-related lymphomas. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2018.
14.Lu L, Jia M, Ma Y, Yang L, Chen Z, Ho DD, Jiang Y, Zhang L: The changing face of HIV in China. Nature 2008, 455(7213):609–611.
15.Jia M, Luo H, Ma Y, Wang N, Smith K, Mei J, Lu R, Lu J, Fu L, Zhang Q et al: The HIV epidemic in Yunnan Province, China, 1989–2007. Journal of acquired immune deficiency syndromes 2010, 53 Suppl 1:S34–40.
16.Xiao J, Du S, Dai G, Gao G, Yang D, Zhao H: Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. Scientific reports 2017, 7(1):1905.
17.Shen Y, Zhang R, Liu L, Shen Y, Song W, Qi T, Tang Y, Wang Z, Guan L, Lu H: Clinical and prognostic analysis of 78 patients with human immuno-deficiency virus associated non-Hodgkin’s lymphoma in Chinese population. Infectious agents and cancer 2017, 12:7.
18.Chen M, Jia MH, Ma YL, Luo HB, Chen HC, Yang CJ, Dai J, Yang L, Dong LJ, Lu R et al: The changing HIV–1 genetic characteristics and transmitted drug resistance among recently infected population in Yunnan, China. Epidemiology and infection 2018, 146(6):775–781.
19.Ji Y, Lu H: Malignancies in HIV-Infected and AIDS Patients. Advances in experimental medicine and biology 2017, 1018:167–179.
20.Han X, Jemal A, Hulland E, Simard EP, Nastoupil L, Ward E, Flowers CR: HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2017, 26(3):303–311.
21.Healy JA, Dave SS: The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma. Current topics in microbiology and immunology 2015, 390(Pt 1):315–337.
22.de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S et al: Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2008, 6(4):451–458.
23.Chen YY, Huang CE, Liang FW, Lu CH, Chen PT, Lee KD, Chen CC: Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. Cancer epidemiology 2015, 39(3):382–387.
24.Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E: The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005, 90(5):704–706.
25.Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf IG, Anagnostopoulos I, Huhn D: Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival—results of the German Multicenter Trial. Cancer 2006, 106(7):1560–1568.
26.Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH et al: Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010, 115(15):3008–3016.
27.Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L et al: Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood 2016, 128(8):1050–1058.
28.Barta SK, Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Navarro JT, Hoffmann C, Dunleavy K, Little RF et al: Central nervous system involvement in AIDS-related lymphomas. British journal of haematology 2016, 173(6):857–866.
29.Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Tellez MJ, Lacruz J, Valencia E, Santos J, Rodriguez-Arrondo F et al: Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. Journal of acquired immune deficiency syndromes 2007, 44(2):167–173.
30.Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R et al: Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Annals of oncology: official journal of the European Society for Medical Oncology 2015, 26(5):958–966.
31.Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG: The Epstein-Barr virus and the pathogenesis of lymphoma. The Journal of pathology 2015, 235(2):312–322.
32.Linke-Serinsoz E, Fend F, Quintanilla-Martinez L: Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology view point. Seminars in diagnostic pathology 2017, 34(4):352–363.
33.Morton LM, Kim CJ, Weiss LM, Bhatia K, Cockburn M, Hawes D, Wang SS, Chang C, Altekruse SF, Engels EA et al: Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era. Leukemia & lymphoma 2014, 55(3):551–557.
34.Ul-Haq I, Dalla Pria A, Suardi E, Pinato DJ, Froeling F, Forni J, Randell P, Bower M: Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma. Medical oncology 2018, 35(4):53.
35.Chao C, Silverberg MJ, Martinez-Maza O, Chi M, Abrams DI, Haque R, Zha HD, McGuire M, Xu L, Said J: Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2012, 18(17):4702–4712.
36.Chao C, Silverberg MJ, Chen LH, Xu L, Martinez-Maza O, Abrams DI, Zha HD, Haque R, Said J: Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. Leukemia & lymphoma 2018, 59(2):321–329.
37.Dlouhy I, Torrente MA, Lens S, Rovira J, Magnano L, Gine E, Delgado J, Balague O, Martinez A, Campo E et al: Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Annals of hematology 2017, 96(3):405–410.